12:00 AM
May 03, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Welchol colesevelam: Phase IV data

Data from a double-blind Phase IV trial in 216 patients showed that 3.75 g/day Welchol met the primary endpoint of significantly reducing LDL cholesterol from baseline to week 16 vs. placebo (13.9% reduction vs. 1.7% increase, p<0.001). Welchol also significantly reduced HbA1c (0.12% vs. 0.03%, p=0.02),...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >